Radian Group (NYSE:RDN) reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $0.78 by 74.36 percent. This is a 81.33 percent increase over earnings of $0.75 per share from the same period last year.
CinCor Pharma Announces Topline Data For Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat On Uncontrolled Hypertension Did Not Meet Its Primary Endpoint
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP)
12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup
